Earnings Pressure from Official Drug Price Cuts
First written in FY2016-Q3. 16 of 32 entries say "Restated". Latest entry: 2026-08-06.
Fuji Pharma moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2025-H1WorsenedAnnual report
「For our products, the overall drug price revision rate was limited to a negative 1.1% due to the impact of price increases for some products through repricing of unprofitable products.」
The overall drug price revision rate changed from positive 1.2% previously to negative 1.1% this time, quantifying once again the earnings pressure from efforts to restrain drug prices. - FY2024-Q2MitigatedAnnual report
「In the prescription pharmaceutical industry, drug price revisions aimed at restraining pharmaceutical spending have been implemented annually since April 2021 in response to rising social security costs, making the business environment increasingly challenging. For our products, however, the overall drug price revision rate was positive 1.2% due to the impact of price increases for some products through repricing of unprofitable products.」
While the challenging industry environment resulting from annual drug price revisions continues, the disclosure states that repricing of unprofitable products resulted in an overall positive 1.2% drug price revision rate for our products. - FY2024-Q1RestatedAnnual report
「In the prescription pharmaceutical industry, efforts to restrain drug prices in response to rising social security costs continue, while annual drug price revisions are implemented, making the business environment increasingly challenging.」
The disclosure continues to describe a challenging business environment resulting from efforts to restrain drug prices amid rising social security costs and annual drug price revisions. - FY2023-Q3RestatedAnnual report
「In the prescription pharmaceutical industry, efforts to restrain drug prices in response to rising social security costs continue, and annual drug price revisions have been implemented since April 2021, making the business environment increasingly challenging. For our products, however, drug prices were raised by 3.6% as a result of repricing of unprofitable products against a backdrop of supply stability issues and a sharp increase in raw material costs.」
While continuing to describe pressure from annual drug price revisions, the disclosure repeats the explanation that drug prices for our products were raised by 3.6% through repricing of unprofitable products against a backdrop of supply stability issues and higher raw material costs. - FY2023-Q2MitigatedAnnual report
「In the prescription pharmaceutical industry, efforts to restrain drug prices in response to rising social security costs continue, and annual drug price revisions have been implemented since April 2021, making the business environment increasingly challenging. For our products, however, drug prices were raised by 3.6% as a result of repricing of unprofitable products against a backdrop of supply stability issues and a sharp increase in raw material costs.」
While pressure from annual drug price revisions continues, the disclosure states that drug prices for our products were raised by 3.6% through repricing of unprofitable products against a backdrop of supply stability issues and higher raw material costs. - FY2023-Q1RestatedAnnual report
「In the prescription pharmaceutical industry, the trend toward drug price cuts due to efforts to reduce healthcare spending continues, and annual drug price revisions have been implemented since April 2021, making the business environment increasingly challenging.」
The disclosure continues to describe a challenging business environment characterized by drug price cuts driven by healthcare spending reductions and annual drug price revisions since April 2021. - FY2022RestatedAnnual report
「Drug prices have been revised annually since April 2021, and the impact of the April 2022 revision on our products was 6.5%.」
The disclosure also describes the continuation of annual drug price revisions and the 6.5% impact of the April 2022 revision on our products for the full fiscal year. - FY2022-Q3RestatedAnnual report
「The April 2022 drug price revision resulted in an average 6.7% reduction across the industry based on listed drug prices, while the impact of price reductions on our products was 6.5%.」
The disclosure repeats the 6.7% industry-average impact and 6.5% impact on our products from the April 2022 drug price revision, following the previous quarter. - FY2022-Q2MaterialisedAnnual report
「The April 2022 drug price revision resulted in an average 6.7% reduction across the industry based on listed drug prices, while the impact of price reductions on our products was 6.5%.」
The April 2022 drug price revision was implemented, with the impact of the cuts specifically stated as 6.7% for the industry average and 6.5% for our products. - FY2022-Q1RestatedAnnual report
「In the prescription pharmaceutical industry, the trend toward drug price cuts due to efforts to reduce healthcare spending continues. The interim-year revision was implemented in April 2021, and annual drug price revisions have finally begun, making the business environment increasingly challenging.」
The disclosure continues to describe drug price cuts driven by healthcare spending reductions, the interim-year revision, and the start of annual drug price revisions. - FY2021RestatedAnnual report
「Drug prices have been revised annually since April 2021, and the impact of the April 2021 revision on our products was 6.2%.」
The disclosure continues to describe annual drug price revisions and the 6.2% impact of the April 2021 revision on our products. - FY2021-Q3RestatedAnnual report
「A stringent drug pricing system has been decided under which the products eligible for the new drug creation premium will be substantially reduced and some long-listed products will be reduced to the same price as generic drugs. The first interim-year revision was also decided for April 2021, finally marking the start of annual drug price revisions, making the business environment increasingly challenging. The impact of price reductions on our products in the April 2021 drug price revision was 6.2%.」
The disclosure repeats the start of the April 2021 interim-year revision and its 6.2% impact on our products from the previous quarter. - FY2021-Q2MaterialisedAnnual report
「The impact of price reductions on our products in the April 2021 drug price revision was 6.2%.」
The impact of the April 2021 drug price revision on our products is specifically stated as 6.2%, showing that pressure from drug price cuts has materialized as an actual impact. - FY2021-Q1WorsenedAnnual report
「A stringent drug pricing system has been decided under which the products eligible for the new drug creation premium will be substantially reduced and some long-listed products will be reduced to the same price as generic drugs. The first interim-year revision was also decided for April 2021, finally marking the start of annual drug price revisions, making the business environment increasingly challenging.」
In addition to conventional drug price revisions, fewer products eligible for the new drug creation premium, and price cuts for long-listed products, the disclosure describes the first interim-year revision in April 2021 and the decision to begin annual drug price revisions, further specifying the pressure from drug price cuts. - FY2020WorsenedAnnual report
「More recently, the start of annual revisions from April 2021 has been under consideration, with the possibility of drug price cuts for products with large price discrepancies.」
In addition to the actual drug price cuts in October 2019 and April 2020, the disclosure identifies consideration of annual revisions beginning in April 2021 as a new source of pressure. - FY2020-Q3RestatedAnnual report
「The October 2019 drug price revision resulted in an average 2.4% reduction across the industry based on listed drug prices, while the impact of price reductions on our products was 5.5%. Furthermore, the April 2020 drug price revision resulted in an average 4.4% reduction across the industry based on listed drug prices, while the impact on our products was 1.4%.」
The disclosure repeats the October 2019 and April 2020 drug price revisions and quantifies their impact on the industry average and our products. The April 2020 figures have been rounded from 4.38% and 1.41% in the previous quarter. - FY2020-Q2MaterialisedAnnual report
「Furthermore, the April 2020 drug price revision resulted in an average 4.38% reduction across the industry based on listed drug prices, while the impact of price reductions on our products was 1.41%.」
The April 2020 drug price revision, which had been expected in the previous quarter, was implemented, and the disclosure states that the impact specifically materialized at 4.38% for the industry average and 1.41% for our products. - FY2020-Q1WorsenedAnnual report
「In the prescription pharmaceutical industry, the business environment is becoming increasingly challenging. In addition to the drug price revision accompanying the October 2019 consumption tax increase, another revision is expected in April 2020, and a stringent drug pricing system has been decided under which the products eligible for the new drug creation premium will be substantially reduced and some long-listed products will be reduced to the same price as generic drugs. The October 2019 drug price revision resulted in an average 2.4% reduction across the industry based on listed drug prices, while the impact of price reductions on our products was 5.5%.」
The 5.5% impact of the October 2019 drug price revision on our products was reconfirmed as part of the business environment for the quarter, while the expected April 2020 revision was added, indicating that pressure from drug price cuts is continuing and intensifying. - FY2019MaterialisedAnnual report
「In addition, drug prices were cut in October 2019 by an industry average of 2.4% based on listed drug prices. The impact of price reductions on our products was 5.5%.」
The October 2019 drug price cuts were implemented, with the impact specifically disclosed as 2.4% for the industry average and 5.5% for our products. - FY2019-Q3RestatedAnnual report
「In the prescription pharmaceutical industry, the business environment is becoming increasingly challenging as, in addition to annual drug price revisions, the number of products eligible for the new drug creation premium has been substantially reduced and a stringent drug pricing system has been established under which prices for some long-listed products are reduced to the same level as those for generic pharmaceuticals.」
The disclosure continues to describe a challenging business environment resulting from annual drug price revisions, fewer products eligible for the new drug creation premium, and price cuts for long-listed products. - FY2019-Q2RestatedAnnual report
「In the prescription pharmaceutical industry, the business environment is becoming increasingly challenging as, in addition to annual drug price revisions, the number of products eligible for the new drug creation premium has been substantially reduced and a stringent drug pricing system has been established under which prices for some long-listed products are reduced to the same level as those for generic pharmaceuticals.」
As in the previous quarter, the disclosure describes a challenging business environment resulting from annual drug price revisions, fewer products eligible for the new drug creation premium, and price cuts for long-listed products. - FY2019-Q1MaterialisedAnnual report
「In terms of profit, operating income was ¥1,605 million, down 7.0% year on year, due to the impact of the April 2018 drug price revision and an increase in selling, general and administrative expenses. Ordinary income was ¥1,532 million, down 16.0%, and net income attributable to owners of the parent was ¥1,096 million, down 15.8%.」
The disclosure states that the April 2018 drug price revision was reflected in actual results as a factor behind the decline in profit for the quarter. - FY2018-Q3RestatedAnnual report
「In addition, drug prices were revised in April 2018, resulting in an average 7.5% reduction across the industry based on listed drug prices. The impact of price reductions on our products was 6.7%.」
The impact of the April 2018 drug price cuts, 7.5% for the industry average and 6.7% for our products, was disclosed again following the previous quarter. - FY2018-Q2WorsenedAnnual report
「In addition, drug prices were revised in April 2018, resulting in an average 7.5% reduction across the industry based on listed drug prices. The impact of price reductions on our products was 6.7%.」
In addition to annual drug price revisions and related measures, drug prices were cut in April 2018, with the impact newly quantified at 7.5% for the industry average and 6.7% for our products. The risk of drug price cuts has materialized as an actual impact. - FY2018-Q1WorsenedAnnual report
「In the prescription pharmaceutical industry, the business environment is becoming increasingly challenging as, in addition to annual drug price revisions, the number of products eligible for the new drug creation premium has been substantially reduced and a stringent drug pricing system has been established under which prices for some long-listed products are reduced to the same level as those for generic pharmaceuticals.」
In addition to annual drug price revisions, the disclosure describes policy decisions involving a reduction in products eligible for the new drug creation premium and price cuts for long-listed products, specifying the earnings pressure from the drug pricing system. - FY2017RestatedAnnual report
「In the Basic Policy on Fundamental Reform of the Drug Pricing System adopted in December 2016, a policy of revising drug prices annually was decided, among other measures, making the business environment increasingly challenging.」
The same view as before is stated regarding the policy of annual drug price revisions and the challenging business environment. - FY2017-Q3RestatedAnnual report
「In the Basic Policy on Fundamental Reform of the Drug Pricing System adopted in December 2016, a policy of revising drug prices annually was decided, among other measures, making the business environment increasingly challenging.」
The same view as before is stated regarding the policy of annual drug price revisions and the challenging business environment. - FY2017-Q2RestatedAnnual report
「In the Basic Policy on Fundamental Reform of the Drug Pricing System adopted in December 2016, a policy of revising drug prices annually was decided, among other measures, making the business environment increasingly challenging.」
The same view as in the previous quarter is stated regarding the policy of annual drug price revisions and the challenging business environment. - FY2017-Q1WorsenedAnnual report
「In the Basic Policy on Fundamental Reform of the Drug Pricing System adopted in December 2016, a policy of revising drug prices annually was decided, among other measures, making the business environment increasingly challenging.」
The decision to revise drug prices annually is newly described, reinforcing the characterization of the business environment under the drug pricing system as challenging. - FY2016-Q3First statedAnnual report
「Drug prices were revised in April 2016, resulting in an industry-average reduction of 5.57% on a drug-price basis. The impact of the drug price reduction on the Company's products was 7.8%.」
The drug price revision and its impact on the industry average and the Company's products are stated numerically.